Literature DB >> 15726530

Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers.

Franco M Muggia1.   

Abstract

Platinum compounds have long played a role in the treatment of gynecologic cancers. Single-agent cisplatin and carboplatin have shown activity in endometrial cancer, and more recent studies have begun to investigate a variety of new platinum-based combinations. In cervical cancer, chemotherapy is used primarily to treat advanced or recurrent disease. Agents with proven single-agent activity in this setting include cisplatin, ifosfamide, and doxorubicin, and a number of cisplatin-based combination therapies are under clinical investigation. A variety of cisplatin-based combinations have also been used in ovarian cancer chemotherapy, with more recent studies investigating the substitution of carboplatin or oxaliplatin for cisplatin and the addition of paclitaxel. This review will examine recent clinical data on the use of platinum-based chemotherapies for the treatment of these gynecologic cancers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15726530     DOI: 10.1053/j.seminoncol.2004.11.007

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  7 in total

1.  A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261.

Authors:  Keith C Bible; Prema P Peethambaram; Ann L Oberg; William Maples; David L Groteluschen; Matthew Boente; Jill K Burton; Leigh C Gomez Dahl; Jennifer D Tibodeau; Crescent R Isham; Jacie L Maguire; Viji Shridhar; Andrea K Kukla; Kalli J Voll; Mathew J Mauer; Alexander D Colevas; John Wright; L Austin Doyle; Charles Erlichman
Journal:  Gynecol Oncol       Date:  2012-06-01       Impact factor: 5.482

Review 2.  'BRCAness' and its implications for platinum action in gynecologic cancer.

Authors:  Franco Muggia; Tamar Safra
Journal:  Anticancer Res       Date:  2014-02       Impact factor: 2.480

3.  MTDH/AEG-1 downregulation using pristimerin-loaded nanoparticles inhibits Fanconi anemia proteins and increases sensitivity to platinum-based chemotherapy.

Authors:  Jianling Bi; Sudartip Areecheewakul; Yujun Li; Shujie Yang; Yuping Zhang; Kareem Ebeid; Long Li; Kristina W Thiel; Jun Zhang; Donghai Dai; Aliasger K Salem; Kimberly K Leslie; Xiangbing Meng
Journal:  Gynecol Oncol       Date:  2019-08-30       Impact factor: 5.482

4.  Apoptosis of HeLa cells induced by cisplatin and its mechanism.

Authors:  Youqing Liu; Hui Xing; Xiaobing Han; Xiaoyan Shi; Fengqi Liang; Gang Cheng; Yunping Lu; Ding Ma
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-05-15

5.  Machine-learning aided in situ drug sensitivity screening predicts treatment outcomes in ovarian PDX tumors.

Authors:  Max J Cotler; Khalil B Ramadi; Xiaonan Hou; Elena Christodoulopoulos; Sebastian Ahn; Ashvin Bashyam; Huiming Ding; Melissa Larson; Ann L Oberg; Charles Whittaker; Oliver Jonas; Scott H Kaufmann; S John Weroha; Michael J Cima
Journal:  Transl Oncol       Date:  2022-04-26       Impact factor: 4.803

Review 6.  Therapeutic Potential of Bee and Scorpion Venom Phospholipase A2 (PLA2): A Narrative Review.

Authors:  Parisa Soltan-Alinejad; Hamzeh Alipour; Davood Meharabani; Kourosh Azizi
Journal:  Iran J Med Sci       Date:  2022-07

7.  Preventive Effects of Bee Venom Derived Phospholipase A₂ on Oxaliplatin-Induced Neuropathic Pain in Mice.

Authors:  Dongxing Li; Woojin Kim; Dasom Shin; Yongjae Jung; Hyunsu Bae; Sun Kwang Kim
Journal:  Toxins (Basel)       Date:  2016-01-19       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.